• Oncology

    In the area of oncology, Paradigm has designed and implemented a significant number of CME/CE activities focused on Melanoma, Non-Small Cell Lung Cancer, Gastric Cancer, Kidney Cancer, Basal Cell Carcinoma, B-Cell Malignancies, Metastatic Castration-Resistant Prostate Cancer, and Chemotherapy-Induced Febrile Neutropenia.

TRANSLATING PROGRESS INTO PRACTICE FOR PATIENTS WITH NON-SMALL-CELL LUNG CANCERS

This live CME symposium was designed to synthesize the burgeoning NSCLC expert knowledge base, with the ultimate goal of facilitating individualized care and improving survival rates for a broader selection of patients. The target audience included thoracic surgeons, surgical oncologists, medical oncologists, radiation oncologists, pulmonologists, GP/IM physicians, and respiratory therapists.

 

Updates in Chemotherapy-Induced Nausea and Vomiting: The Oncology Nurse and Oncology Nurse Practitioner's Perspectives

Chemotherapy-induced nausea and vomiting (CINV) is a highly debilitating side effect of chemotherapy. CINV is common, causing symptoms in up to 30% of all patients who undergo chemotherapy, and occurring in up to 90% of patients who receive highly emetogenic agents such as cisplatin-, doxorubicin-, and cyclophosphamide-containing regimens. The American Society of Clinical Oncology (ASCO) voted modern antiemetic therapy as one of the top 10 advances in modern oncology because antiemetic therapy is an advance that marked one of the "major turning points for cancer care and improved and saved the lives of countless Americans." In this interactive video webinar advanced practice oncology NPs and oncology RNs share and discuss their extensive and unique experiences in managing patients suffering from or at risk of developing CINV, including nuances of antiemetic agents and experiential strategies for positioning antiemetic therapies, as well as how to educate patients regarding CINV and its prevention and treatment.

 

NEW APPROACH TO LYMPHOMAS: TARGETING CD30

Targeted agents for the treatment of CD30-expressing lymphomas, including Hodgkin lymphoma and systemic and cutaneous T-cell lymphomas, has entered the clinic with several strategies in late-stage clinical trials. However, there is a lack of knowledge of how to best manage patients with CD30-expressing lymphoma based on disease characteristics and new treatment approaches. This monograph includes an in-depth discussion of the current and emerging treatment of CD30-expressing lymphomas. In addition, the mechanism of action of the antibody-drug conjugate, brentuximab vedotin, and management considerations of patients taking brentuximab vedotin will be explored with commentary from experts in the field of lymphoma.

 

A PATIENT-CENTERED APPROACH TO CHRONIC LYMPHOCYTIC LEUKEMIA: NEW PERSPECTIVES ON MEDICAL MANAGEMENT, QUALITY OF LIFE, AND PSYCHOSOCIAL CARE

This program reviews the diagnosis and staging of chronic lymphocytic leukemia (CLL), current practices in the pharmacotherapy of CLL, and the status of agents in development. It also describes how CLL affects patientsí and caregiversí emotional and mental well-being and takes an in-depth look at how clinicians can measure the impact of the disease on healthcare-related quality of life (HRQoL) and improve patient HRQoL.

 

HARNESSING THE POWER OF INTRALESIONAL THERAPY FOR UNRESECTABLE MELANOMA

This live, interactive symposium, comprising didactic lectures, challenging real-world clinical cases, and a question-and-answer session with the faculty panel, was held as an ancillary symposium at the 2013 ASCO Annual Meeting and Exhibition. The enduring, on-demand web activity was based on the proceedings of the live symposium, hosted on www.realcme.com, and distributed via the Epocrates/MDLinx mobile and online networks. A link was also placed on Paradigm's website, www.paradigmmc.com, and the activity was promoted to Paradigm's internal database of oncology professionals.

 

BENEATH THE SKIN: NEW INSIGHTS INTO BASAL CELL CARCINOMA

This series of live, freestanding, regional CME-certified activities was targeted to a combined multidisciplinary audience of dermatologists, dermatologic surgeons, and medical oncologists and focused on improving diagnosis and management of BCC. The initiative also included a 3-part printed/digital case-based monograph series developed and distributed in conjunction with the Journal of Drugs in Dermatology, a peer-reviewed and MEDLINE-indexed publication that reaches every US-based dermatologist, resident, fellow, PA, and NP in dermatology.

 

EVIDENCE-BASED MANAGEMENT OF ADVANCED GASTRIC CANCER: CURRENT AND EMERGING TARGETED THERAPIES

These live CME oncology grand rounds activities included didactic lecture, real-world case studies, and a question-and-answer session with an expert faculty presenter. An interactive CME/CE enduring web monograph, features key educational messages and video vignettes from the live meetings. Hosted on the Paradigm website, www.paradigmmc.com, the activity was also distributed via Elsevier on the MEDLINE-indexed Seminars in Oncology website (www.seminoncol.org) and other appropriate journal and web portals, and posted on the website of the International Society of Gastrointestinal Oncology (www.isgio.org).

 

IMPROVING OUTCOMES IN PATIENTS WITH B-CELL MALIGNANCIES: CENTRAL ROLE OF THE ONCOLOGY NURSE IN AN ERA OF RAPID THERAPEUTIC ADVANCES

This CNE initiatve consisted of a series of symposia held in conjunction with regularly scheduled ONS local chapter meetings. Activities were designed to update nurses on clinical practice guidelines, chemotherapy, targeted agents, and immunotherapy, as well as future trends in the management of these disorders, to help them provide the best possible bedside care.

 

MULTIDISCIPLINARY APPROACH TO CHARTING A TREATMENT COURSE FOR MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A CASE CONSULTS™ WEB ACTIVITY

This CME/CE-certified Case Consults™ video webinar includes a short overview discussion among the multidisciplinary faculty about the challenges in treating mCRPC followed by interactive patient cases. Designed to increase participant ability to apply a comprehensive set of monitoring parameters and make rational, evidence-based treatment decisions for their patients with metastatic castration-resistant prostate cancer based on current clinical evidence and guidelines, the activity is accessible via the Paradigm website, www.paradigmmc.com; the University of Cincinnati's CME website, www.cme.uc.edu; and the myCME website, www.myCME.com.

 

ADVANCES IN IMMUNOTHERAPY FOR ADVANCED MELANOMA: INTEGRATING INTRALESIONAL AND ANTI-PD-1 IMMUNOTHERAPIES INTO CURRENT PRACTICE

This CME-certified satellite symposium at the Society of Surgical Oncology (SSO) 2015 Annual Meeting included didactic presentations, interactive case presentations, and a moderated Q&A discussion with the faculty panel. Throughout the symposium, attendees used iPads to view the program, take notes, interact with faculty, and complete the posttest, increasing audience interaction. An enduring audio webinar based upon the proceedings of the live symposium is hosted on www.paradigmmc.com.

 

ADVANCING THE TREATMENT STRATEGIES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: THE UROLOGIST'S ROLE

This text-based, interactive, CME-certified web monograph features audio and video clips of expert faculty interviews and discussions and was designed to provide urologists, medical and radiation oncologists, and other healthcare professionals with the latest information on monitoring parameters that may help guide treatment decisions or indicate efficacy of therapy. The faculty also provide information on differences among available therapies to facilitate evidence-based, individualized treatment decisions and the roles of multidisciplinary team members in managing mCRPC patients.

 

4TH INTERNATIONAL SYMPOSIUM ON CANCER METASTASIS AND THE LYMPHOVASCULAR SYSTEM: BASIS FOR RATIONAL THERAPY

This 2.5-day multigrantor CME-certified conference in New York, NY, chaired by Stanley P. L. Leong, MD, FACS, featured dozens of world-renowned cancer experts. It was designed to help participants improve their expertise in detecting and managing cancer metastasis from its inception in the tumor microenvironment through its progression to metastatic potential at distant sites by way of the lymphovascular system. In collaboration with the Sentinel Node Oncology Foundation/Sentinel Lymph Node Working Group and Sutter Pacific Medical Foundation, the conference was also sponsored by the National Cancer Institute, The Arizona Cancer Center, AIM at Melanoma, and The Melanoma Research Foundation.

 

ADVANCES IN DIAGNOSIS AND TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)

This live CME symposium was designed to synthesize the burgeoning NSCLC expert knowledge base, with the ultimate goal of facilitating individualized care and improving survival rates for a broader selection of patients. The target audience included thoracic surgeons, surgical oncologists, medical oncologists, radiation oncologists, pulmonologists, GP/IM physicians, and respiratory therapists.

 

PROMISING NEW THERAPIES IN KIDNEY CANCER: UPDATE AND PANEL DISCUSSION

This CME satellite symposium at The Oncology World Congress was jointly sponsored with the Elsevier Office of Continuing Medical Education. It provided an overview of the latest data on key promising agents in kidney cancer as well as a panel discussion in which experts put these promising therapies into context. The target audience included community oncologists, pediatric oncologists, radiation oncologists, surgical oncologists, and urologists.

 

MELANOMACARE.ORG

This interactive website served as the platform for the many components of the Melanoma Care Coalition, an award-winning, comprehensive, multidisciplinary educational initiative designed for medical oncologists, surgical oncologists, dermatologists, oncology nurses, and other healthcare professionals caring for patients with melanoma. This initiative was developed and implemented in collaboration with the University of Pittsburgh School of Medicine.

 

2012 MELANOMA CARE COALITION WEBINAR SERIES

This series of CME/CNE-certified on-demand-webinars, available at www.melanomacare.org, focused on the pivotal issues that clinicians face in the care of patients with melanoma, such as advances in immunotherapy, management of metastatic melanoma, chemotherapy of melanoma, updates on emerging therapies, management, and biomarkers of melanoma.

 

MELANOMA CARE OPTIONS™

This national CME-certified publication series featured clinical and nonclinical content from renowned faculty specializing in melanoma care. Edited by John M. Kirkwood, MD, issues were made available in print and online.

 

THE MELANOMA CARE COALITION TAKES ON THE CONTROVERSIES

As part of the Melanoma Care Coalition, these regional, live CME-certified activities featured an interactive, case-based approach to complex and often controversial issues in melanoma care. Chaired by Dr. John M. Kirkwood, this series of symposia brought clinical controversies into focus on a practical level for physicians who screen for and treat melanoma. Many of these meetings were held in conjunction with nationally-recognized cancer centers.

 

MELANOMA CARE OPTIONS™ ONCOLOGY NURSING UPDATE

This initiative, chaired by Rosemary Giuliano, ARNP, MSN, included a CNE-certified series of newsletters that provided information to help oncology nurses stay up-to-date regarding advances in the care of patients with melanoma. The initiative was developed and implemented in collaboration with University of Pittsburgh School of Nursing.

 

BRIDGING AVAILABLE TREATMENTS TO BEST-CASE OUTCOMES IN MELANOMA

This satellite symposium was presented in collaboration with the University of Pittsburgh School of Nursing at the 33rd Annual Oncology Nursing Society Congress. Chaired by Rosemary Giuliano, ARNP, MSN, and featuring John M. Kirkwood, MD, this interactive, case-based symposium focused on the oncology nurse's pivotal role in helping manage patient expectations, keeping patients on therapy, and guiding patients and their families through care decisions, including end-of-life issues.